Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
83 hedge funds and large institutions have $216M invested in Avadel Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 25 reducing their positions, and 13 closing their positions.
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
1% more funds holding
Funds holding: 82 → 83 (+1)
4% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 25
1.36% less ownership
Funds ownership: 46.37% → 45.01% (-1.4%)
24% less capital invested
Capital invested by funds: $285M → $216M (-$68.3M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
98% less call options, than puts
Call options by funds: $8K | Put options by funds: $433K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$31M |
| 2 |
PA
Perceptive Advisors
New York
|
+$7.9M |
| 3 |
NC
Nexthera Capital
New York
|
+$4.74M |
| 4 |
Renaissance Technologies
New York
|
+$3.01M |
| 5 |
DM
Deerfield Management
New York
|
+$2.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$22.6M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$10.3M |
| 3 |
BC
Broadfin Capital
New York
|
-$9.16M |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$7.35M |
| 5 |
FPC
Falcon Point Capital
San Francisco,
California
|
-$6.28M |
AVDL Hedge Fund Activity: Q4 2017 in Review
83 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2017, worth a combined $216M — down 24% from $285M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AVDL positions and 13 closed out — a net gain of 2 holders — while 24 added to existing stakes and 25 trimmed.
The largest buyer was Brandes Investment Partners, opening a new position worth an estimated $31M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $22.6M sold.
- 83 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2017, up from 82 in Q3 2017.
- Funds reported $216M of Avadel Pharmaceuticals stock for Q4 2017, down 24% quarter-over-quarter.
- 15 funds opened new Avadel Pharmaceuticals positions in Q4 2017 and 13 closed out, a net change of +2 holders.
- The largest Avadel Pharmaceuticals buyer in Q4 2017 was Brandes Investment Partners, an estimated $31M added.
- The largest Avadel Pharmaceuticals seller in Q4 2017 was Janus Henderson Group, an estimated $22.6M sold.
Based on aggregated 13F filings for Q4 2017.